BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 26743775)

  • 21. Counter-regulatory hormone responses to spontaneous hypoglycaemia during treatment with insulin Aspart or human soluble insulin: a double-blinded randomized cross-over study.
    Brock Jacobsen I; Vind BF; Korsholm L; Flyvbjerg A; Frystyk J; Holst JJ; Beck-Nielsen H; Henriksen JE
    Acta Physiol (Oxf); 2011 Jul; 202(3):337-47. PubMed ID: 21481195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preserved glucose response to low-dose glucagon after exercise in insulin-pump-treated individuals with type 1 diabetes: a randomised crossover study.
    Steineck IIK; Ranjan A; Schmidt S; Clausen TR; Holst JJ; Nørgaard K
    Diabetologia; 2019 Apr; 62(4):582-592. PubMed ID: 30643924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Symptomatic and counterregulatory hormonal responses to acute hypoglycaemia induced by insulin aspart and soluble human insulin in Type 1 diabetes.
    Frier BM; Ewing FM; Lindholm A; Hylleberg B; Kanc K
    Diabetes Metab Res Rev; 2000; 16(4):262-8. PubMed ID: 10934454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes.
    Haymond MW; DuBose SN; Rickels MR; Wolpert H; Shah VN; Sherr JL; Weinstock RS; Agarwal S; Verdejo AS; Cummins MJ; Newswanger B; Beck RW;
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2994-3001. PubMed ID: 28591776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do high fasting glucose levels suggest nocturnal hypoglycaemia? The Somogyi effect-more fiction than fact?
    Choudhary P; Davies C; Emery CJ; Heller SR
    Diabet Med; 2013 Aug; 30(8):914-7. PubMed ID: 23672623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin-based strategies to prevent hypoglycaemia during and after exercise in adult patients with type 1 diabetes on pump therapy: the DIABRASPORT randomized study.
    Franc S; Daoudi A; Pochat A; Petit MH; Randazzo C; Petit C; Duclos M; Penfornis A; Pussard E; Not D; Heyman E; Koukoui F; Simon C; Charpentier G
    Diabetes Obes Metab; 2015 Dec; 17(12):1150-7. PubMed ID: 26264812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus.
    Stenninger E; Aman J
    Diabetologia; 1993 Oct; 36(10):931-5. PubMed ID: 8243872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
    Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Counterregulatory hormones in insulin-treated diabetic patients admitted to an accident and emergency department with hypoglycaemia.
    Hvidberg A; Christensen NJ; Hilsted J
    Diabet Med; 1998 Mar; 15(3):199-204. PubMed ID: 9545120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonaqueous, Mini-Dose Glucagon for Treatment of Mild Hypoglycemia in Adults With Type 1 Diabetes: A Dose-Seeking Study.
    Haymond MW; Redondo MJ; McKay S; Cummins MJ; Newswanger B; Kinzell J; Prestrelski S
    Diabetes Care; 2016 Mar; 39(3):465-8. PubMed ID: 26861921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term fully closed-loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes.
    Bally L; Herzig D; Ruan Y; Wilinska ME; Semmo M; Vogt A; Wertli MM; Vogt B; Stettler C; Hovorka R
    Diabetes Obes Metab; 2019 Dec; 21(12):2718-2722. PubMed ID: 31464063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia.
    Porcellati F; Pampanelli S; Rossetti P; Busciantella Ricci N; Marzotti S; Lucidi P; Santeusanio F; Bolli GB; Fanelli CG
    Diabetologia; 2007 Feb; 50(2):422-30. PubMed ID: 17160672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabet Med; 2001 Feb; 18(2):144-9. PubMed ID: 11251679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.
    Russell SJ; Hillard MA; Balliro C; Magyar KL; Selagamsetty R; Sinha M; Grennan K; Mondesir D; Ekhlaspour L; Zheng H; Damiano ER; El-Khatib FH
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):233-243. PubMed ID: 26850709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial.
    Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R
    Diabetes Obes Metab; 2017 May; 19(5):713-720. PubMed ID: 28094472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM.
    Kanc K; Janssen MM; Keulen ET; Jacobs MA; Popp-Snijders C; Snoek FJ; Heine RJ
    Diabetologia; 1998 Mar; 41(3):322-9. PubMed ID: 9541173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
    Frandsen CS; Dejgaard TF; Andersen HU; Holst JJ; Hartmann B; Thorsteinsson B; Madsbad S
    Diabetes Obes Metab; 2017 Jun; 19(6):773-782. PubMed ID: 27868372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin administered by needle-free jet injection corrects marked hyperglycaemia faster in overweight or obese patients with diabetes.
    de Wit HM; Engwerda EE; Tack CJ; de Galan BE
    Diabetes Obes Metab; 2015 Nov; 17(11):1093-9. PubMed ID: 26259978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
    Pieber TR; Deller S; Korsatko S; Jensen L; Christiansen E; Madsen J; Heller SR
    Diabetes Obes Metab; 2015 Aug; 17(8):742-50. PubMed ID: 25855340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.